Roivant Sciences Ltd. $ROIV Shares Sold by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 95.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,000 shares of the company’s stock after selling 425,500 shares during the quarter. Capricorn Fund Managers Ltd’s holdings in Roivant Sciences were worth $554,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ROIV. SBI Securities Co. Ltd. boosted its stake in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its holdings in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Roivant Sciences in the 4th quarter valued at about $47,000. CIBC Private Wealth Group LLC boosted its stake in shares of Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the last quarter. Finally, Clearstead Advisors LLC grew its holdings in shares of Roivant Sciences by 141.6% during the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after buying an additional 1,704 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. Citigroup boosted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Guggenheim lifted their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Activity at Roivant Sciences

In related news, CEO Matthew Gline sold 289,774 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the transaction, the director owned 13,689,166 shares in the company, valued at $482,953,776.48. The trade was a 0.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,341,475 shares of company stock valued at $76,791,271 over the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $35.39 on Wednesday. The firm’s 50-day simple moving average is $29.88 and its 200-day simple moving average is $27.02. Roivant Sciences Ltd. has a 1-year low of $10.70 and a 1-year high of $35.90. The firm has a market cap of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same period in the previous year, the firm earned ($0.29) earnings per share. Analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.